The biotechnology company currently developing an intravenously delivered immuno-oncolytic virus has announced it has entered into a master clinical supply agreement
Oncolytics Biotech, currently developing Reolysin (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, has announced that it has entered into a master clinical supply agreement with F. Hoffmann-La Roche to supply atezolizumab (Tecentriq) for use in the company’s clinical development programme.
“The supply agreement enables us to further investigate pelareorep’s impact on cancer treatments in combination with atezolizumab,” said Dr Matt Coffey President and CEO of Oncolytics Biotech.
“We plan on incorporating this anti-PD-L1 cancer immunotherapy into our clinical program immediately. Data from these studies will broaden our experience with this drug class as we look to demonstrate the impact of pelareorep with checkpoint inhibitors.”
Under this 5 year Master Clinical Supply Agreement, Roche will supply atezolizumab for the proposed clinical trial with both parties having access to the clinical data.